Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus.
about
Antimicrobial bacteriophage-derived proteins and therapeutic applicationsA chimeolysin with extended-spectrum streptococcal host range found by an induced lysis-based rapid screening methodBiochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus.Bacteriophages and Their Immunological Applications against Infectious Threats.Phage therapy--constraints and possibilities.A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia.Engineered bacteriophage lysins as novel anti-infectivesLysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis.Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococciNovel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model.Beyond the chromosome: the prevalence of unique extra-chromosomal bacteriophages with integrated virulence genes in pathogenic Staphylococcus aureusSynergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis.Prophage lysin Ply30 protects mice from Streptococcus suis and Streptococcus equi subsp. zooepidemicus infections.The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa.Using a Novel Lysin To Help Control Clostridium difficile InfectionsDetermining bacteriophage endopeptidase activity using either fluorophore-quencher labeled peptides combined with liquid chromatography-mass spectrometry (LC-MS) or Förster resonance energy transfer (FRET) assaysAntibacterial Activity of Stenotrophomonas maltophilia Endolysin P28 against both Gram-positive and Gram-negative BacteriaIsolation and characterization of a novel phage lysin active against Paenibacillus larvae, a honeybee pathogen.A lysin to kill.Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammationPL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related SpeciesImproving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding moduleIn vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia.Antibiofilm Activities of a Novel Chimeolysin against Streptococcus mutans under Physiological and Cariogenic Conditions.Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivoA novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus.Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.Exploring the risks of phage application in the environment.Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.Phage lytic proteins: biotechnological applications beyond clinical antimicrobials.Bacteriophages and their derivatives for the treatment and control of food-producing animal infections.A novel prophage lysin Ply5218 with extended lytic activity and stability against Streptococcus suis infection.Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections.Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.Pretreatment with alum or powdered activated carbon reduces bacterial predation-associated irreversible fouling of membranes.A novel endolysin disrupts Streptococcus suis with high efficiency.A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae.Molecular dissection of phage lysin PlySs2: integrity of the catalytic and cell wall binding domains is essential for its broad lytic activity.Print to detect: a rapid and ultrasensitive phage-based dipstick assay for foodborne pathogens.
P2860
Q26781115-E8DEFB90-74B7-4D6C-BCA8-F95A426E8028Q27304933-299119D8-E68C-4588-B526-C3E195BCB5E4Q30009348-FBA2BEE6-E962-4845-B2B1-654A44C904BFQ30234522-755D9391-927A-42AF-8BA1-C756A42DFFF7Q33667556-3BC5E50E-B170-4712-A874-C06685548C57Q33797903-F3CF3A4B-AF75-46C6-AC19-5A2A5192AD4BQ34349552-FC1393F6-8C97-461B-9CCA-9FBF30C563EFQ34555552-C39679DB-3C3C-451E-9B6F-57252276CBD0Q35158325-A8348BF1-AF04-42DD-98C1-E9E221417E12Q35168859-31C878BC-361B-47D2-A7CA-F8FA4FAFE4BAQ35194679-30825E08-BB9C-43E7-BF35-0F68CB4C084AQ36070204-04A617A1-0840-41BF-808B-EB249CD1926DQ36119542-28A00BD6-75F4-4472-B4E6-577D4C8E1870Q36238470-6E6770A5-F915-42B6-8EF6-DDB3C89B2F28Q36290571-EF60602D-FC70-4BB8-9F2E-74A9C9EAA07BQ36309151-D0182BB8-D887-4340-9110-0D4C48B481B9Q36309634-7A004BE8-191B-4065-84BD-EA837586E680Q36550650-C5D24000-55FF-4D51-92C5-48A253D12665Q36844597-B2E2BDF7-0198-4102-A55C-1B003434D1F1Q36991788-F8013757-DEB8-4287-9DC0-922DC807FC25Q37072798-EC99D1B5-3254-4FE1-A017-15BD8447D423Q37131742-2B960390-179C-4282-B181-7EFBBC652CD8Q37263537-845F8525-EA5A-4AC0-871D-75DA028BA05EQ37335777-EABE8C8C-EA97-4276-8367-801698AA6E52Q37428714-0AEA047B-3BFF-4715-849F-4812A75F41E4Q37544464-EFC89434-C22B-47C5-BE7F-E851C200CA5BQ37571286-A16CE792-C330-484A-8C6C-A86DDC79EAC2Q37696606-07D94B4E-CAAC-48CE-9CFF-CE0DC60C0BA7Q38172129-6C0C58BD-1E8A-44CA-9EE6-9231B518909CQ38215724-5E9C8F90-8AF0-4E5C-9104-420876BD95D3Q38325227-3D084AE1-5E9A-42D3-87C5-99E7B52F72BCQ39029801-9F314A4C-7C0C-43B8-8C13-2A27565DEDF4Q39535283-853C28EF-EB50-4A62-AE7B-7332B744311CQ40071759-12C0C2BB-C2EC-470F-A066-2355D98C3F2EQ40075857-18059D08-6F15-4C30-91C6-B98672F85570Q40236009-2FAFFC4C-2E96-433B-A264-0B060CA7229DQ40327769-4FC142B5-6A4E-42D2-B720-ABC8DAD37A15Q41454348-62D1877B-E497-4B1A-88CB-9BD1A6DCAEB0Q41484356-8F27C7C3-98B1-488D-9A83-DB0F1D74CB60Q41931750-995B2A46-6ECC-4AB4-BA73-67AE3ED721DF
P2860
Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@en
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@nl
type
label
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@en
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@nl
prefLabel
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@en
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
Novel bacteriophage lysin with ...... sistant Staphylococcus aureus.
@en
P2093
Chad W Euler
Daniel B Gilmer
Jonathan E Schmitz
Vincent A Fischetti
P2860
P304
P356
10.1128/AAC.02526-12
P407
P577
2013-04-09T00:00:00Z